COVID-19 vaccines pricing policy options for low-income and middle- income countries.
作者信息
Guzman Javier, Hafner Tamara, Maiga Lalla Arkia, Giedion Ursula
机构信息
USAID Medicines, Technologies, and Pharmaceutical Services (MTaPS) Program, Management Sciences for Health, Arlington, Virginia, USA
USAID Medicines, Technologies, and Pharmaceutical Services (MTaPS) Program, Management Sciences for Health, Arlington, Virginia, USA.
出版信息
BMJ Glob Health. 2021 Mar;6(3). doi: 10.1136/bmjgh-2021-005347.
Abstract
摘要
相似文献
1
COVID-19 vaccines pricing policy options for low-income and middle- income countries.低收入和中等收入国家的新冠疫苗定价政策选项
BMJ Glob Health. 2021 Mar;6(3). doi: 10.1136/bmjgh-2021-005347.
2
The costs of coronavirus vaccines and their pricing.新冠病毒疫苗的成本及其定价。
J R Soc Med. 2021 Nov;114(11):502-504. doi: 10.1177/01410768211053006. Epub 2021 Nov 3.
3
Challenges in the rollout of COVID-19 vaccines worldwide.全球新冠疫苗推广面临的挑战。
Lancet Respir Med. 2021 Apr;9(4):e42-e43. doi: 10.1016/S2213-2600(21)00129-6. Epub 2021 Mar 5.
4
Why a pioneering plan to distribute COVID vaccines equitably must succeed.为什么一项公平分发新冠疫苗的开创性计划必须成功。
Nature. 2021 Jan;589(7841):170. doi: 10.1038/d41586-021-00044-9.
5
Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis.预留 2019 冠状病毒病疫苗以实现全球可及：横断面分析。
BMJ. 2020 Dec 15;371:m4750. doi: 10.1136/bmj.m4750.
6
Just allocation of COVID-19 vaccines.2019冠状病毒病疫苗的合理分配
BMJ Glob Health. 2021 Feb;6(2). doi: 10.1136/bmjgh-2020-004812.
7
Future of covid-19 vaccine pricing: lessons from influenza.新冠疫苗定价的未来：流感带来的教训。
BMJ. 2021 Jun 22;373:n1467. doi: 10.1136/bmj.n1467.
8
Covid-19: an economic perspective on vaccinating the world.新冠疫情：全球疫苗接种的经济视角
BMJ. 2021 Jun 15;373:n1498. doi: 10.1136/bmj.n1498.
9
COVID vaccines to reach poorest countries in 2023 - despite recent pledges.尽管近期有承诺，但新冠疫苗要到2023年才能抵达最贫穷国家。
Nature. 2021 Jul;595(7867):342-343. doi: 10.1038/d41586-021-01762-w.
10
It's time to consider a patent reprieve for COVID vaccines.是时候考虑暂缓新冠疫苗的专利了。
Nature. 2021 Apr;592(7852):7. doi: 10.1038/d41586-021-00863-w.
引用本文的文献
1
Overcoming barriers to medical countermeasures: Strengthening global biosecurity.克服医学应对措施的障碍：加强全球生物安全。
Hum Vaccin Immunother. 2025 Dec;21(1):2483043. doi: 10.1080/21645515.2025.2483043. Epub 2025 Mar 25.
2
COVID-19 vaccine preferences for pregnant and lactating women in Bangladesh and Kenya: a qualitative study.孟加拉国和肯尼亚孕妇和哺乳期妇女对 COVID-19 疫苗的偏好：一项定性研究。
Front Public Health. 2024 Aug 14;12:1412878. doi: 10.3389/fpubh.2024.1412878. eCollection 2024.
3
Public Health Emergence: Challenges and Prospects for the Future of Herd Immunity to Reduce the Negative Impact of Disease X in Low- and Middle-Income Countries.突发公共卫生事件：群体免疫在低收入和中等收入国家降低疾病X负面影响的未来挑战与前景
Clin Pathol. 2024 May 14;17:2632010X241254961. doi: 10.1177/2632010X241254961. eCollection 2024 Jan-Dec.
4
Challenges and difficulties faced in low- and middle-income countries during COVID-19.中低收入国家在新冠疫情期间面临的挑战与困难。
Health Policy Open. 2022 Dec;3:100082. doi: 10.1016/j.hpopen.2022.100082. Epub 2022 Nov 8.
5
Strengthening pandemic preparedness: Build the vaccine manufacturing capacity in low- and middle-income countries.加强大流行防范：建设低收入和中等收入国家的疫苗生产能力。
Public Health Pract (Oxf). 2022 Dec;4:100326. doi: 10.1016/j.puhip.2022.100326. Epub 2022 Oct 7.
6
Barriers to COVID-19 Health Products in Low-and Middle-Income Countries During the COVID-19 Pandemic: A Rapid Systematic Review and Evidence Synthesis.新冠肺炎大流行期间中低收入国家的 COVID-19 卫生产品障碍：快速系统评价和证据综合。
Front Public Health. 2022 Jul 22;10:928065. doi: 10.3389/fpubh.2022.928065. eCollection 2022.
7
Cross-Reactivity between Half Doses of Pfizer and AstraZeneca Vaccines-A Preliminary Study.辉瑞和阿斯利康疫苗半剂量之间的交叉反应性——一项初步研究。
Vaccines (Basel). 2022 Mar 27;10(4):521. doi: 10.3390/vaccines10040521.
8
Overcoming non-patient and health professional's barriers to COVID-19 vaccination in pregnancy.克服孕妇及医疗专业人员在新冠疫苗接种方面的障碍。
J Glob Health. 2022 Mar 19;12:03010. doi: 10.7189/jogh.12.03010. eCollection 2022.
9
COVID-19 in Southeast Asia: current status and perspectives.东南亚的 COVID-19 疫情：现状与展望。
Bioengineered. 2022 Feb;13(2):3797-3809. doi: 10.1080/21655979.2022.2031417.
10
Pharmaceutical Industry's Engagement in the Global Equitable Distribution of COVID-19 Vaccines: Corporate Social Responsibility of EUL Vaccine Developers.制药行业参与新冠疫苗的全球公平分配：欧洲药品管理局（EUL）疫苗开发者的企业社会责任
Vaccines (Basel). 2021 Oct 15;9(10):1183. doi: 10.3390/vaccines9101183.
本文引用的文献
1
Treatment of the novel COVID-19: why Costa Rica's proposal for the creation of a global pooling mechanism deserves serious consideration?新型冠状病毒肺炎的治疗：为何哥斯达黎加关于建立全球共享机制的提议值得认真考虑？
J Law Biosci. 2020 Jun 26;7(1):lsaa049. doi: 10.1093/jlb/lsaa049. eCollection 2020 Jan-Jun.
2
The unequal scramble for coronavirus vaccines - by the numbers.新冠疫苗的不平等争夺——数据说明一切。
Nature. 2020 Aug;584(7822):506-507. doi: 10.1038/d41586-020-02450-x.
3
The case for compulsory licensing during COVID-19.新冠疫情期间强制许可的情况。
J Glob Health. 2020 Jun;10(1):010358. doi: 10.7189/jogh.10.010358.
Zotero 插件